Scientific Sessions 2025  /  AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity  /  Modifiable risk factors for atrial fibrillation
Logo

American Heart Association

  45
  0

Final ID:

Modifiable risk factors for atrial fibrillation

  • Albert, Christine  ( Cedars-Sinai Medical Center , Los Aeles , California , United States )
  • Sanders, Prashanthan  ( University of Adelaide , Adelaide , South Australia , Australia )
    • Author Disclosures:
    Christine Albert: DO have relevant financial relationships ; Consultant:Bayor:Active (exists now) ; Consultant:Novartis:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Element Science:Active (exists now) | Prashanthan Sanders: DO have relevant financial relationships ; Advisor:Medtronic:Active (exists now) ; Research Funding (PI or named investigator):Becton Dickenson:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Past (completed) ; Research Funding (PI or named investigator):Abbott:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now) ; Advisor:CathRx:Active (exists now) ; Advisor:Pacemate:Active (exists now) ; Advisor:Boston-Scientific:Active (exists now) ; Advisor:Abbott:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AF Lifestyle Therapy: Drugs Beyond Heart Failure and Obesity

Friday, 11/07/2025 , 12:30PM - 01:45PM

Cardiovascular Seminar

More abstracts on this topic:
SGLT2 inhibitors: the new antiarrhythmic around the block?

Patel Siddharth, Wiviott Stephen

SGLT2 inhibitors vs GLP 1 inhibitors for sleep apnea and atrial fibrillation

Dominic Paari, Kalman Jonathan

More abstracts from these authors:
No Second Breakfast: GLP-1 agonists for HFpEF, obesity and AF

Gulati Martha, Sanders Prashanthan

State of the Art: Preventing Atrial Fibrillation

Sanders Prashanthan

You have to be authorized to contact abstract author. Please, Login
Not Available